DE69227187T2 - Arzneistoffabgabesysteme mit verzögerter freisetzung - Google Patents

Arzneistoffabgabesysteme mit verzögerter freisetzung

Info

Publication number
DE69227187T2
DE69227187T2 DE69227187T DE69227187T DE69227187T2 DE 69227187 T2 DE69227187 T2 DE 69227187T2 DE 69227187 T DE69227187 T DE 69227187T DE 69227187 T DE69227187 T DE 69227187T DE 69227187 T2 DE69227187 T2 DE 69227187T2
Authority
DE
Germany
Prior art keywords
coating layer
effective agent
inner core
drug delivery
release drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227187T
Other languages
English (en)
Other versions
DE69227187D1 (de
Inventor
Thomas J Smith
Paul Ashton
Paul A Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of DE69227187D1 publication Critical patent/DE69227187D1/de
Application granted granted Critical
Publication of DE69227187T2 publication Critical patent/DE69227187T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69227187T 1991-02-21 1992-02-21 Arzneistoffabgabesysteme mit verzögerter freisetzung Expired - Lifetime DE69227187T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/658,695 US5378475A (en) 1991-02-21 1991-02-21 Sustained release drug delivery devices
PCT/US1992/001432 WO1992014450A1 (en) 1991-02-21 1992-02-21 Sustained release drug delivery devices

Publications (2)

Publication Number Publication Date
DE69227187D1 DE69227187D1 (de) 1998-11-05
DE69227187T2 true DE69227187T2 (de) 1999-06-02

Family

ID=24642282

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227187T Expired - Lifetime DE69227187T2 (de) 1991-02-21 1992-02-21 Arzneistoffabgabesysteme mit verzögerter freisetzung

Country Status (10)

Country Link
US (1) US5378475A (de)
EP (2) EP0861659B1 (de)
JP (2) JPH06505274A (de)
AT (2) ATE511832T1 (de)
AU (1) AU660012B2 (de)
CA (1) CA2104699C (de)
DE (1) DE69227187T2 (de)
DK (2) DK0861659T3 (de)
ES (2) ES2125259T3 (de)
WO (1) WO1992014450A1 (de)

Families Citing this family (434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
IL100112A (en) * 1991-11-21 1996-01-31 Yeda Res & Dev Microdelivery device for enhanced drug administration to the eye
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5928662A (en) * 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
DK0973499T3 (da) * 1997-03-31 2003-11-17 Alza Corp Implanterbart diffusionsafgivelsessystem
US20040009924A1 (en) * 1997-05-30 2004-01-15 Veronique Stoven Anticancer products for treating cystic fibrosis
JP2002511075A (ja) * 1997-06-04 2002-04-09 デビオ ルシェルシュ ファルマスティク ソシエテ アノニム 薬学的活性成分の制御放出のためのインプラント及びその製造方法
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6210639B1 (en) 1998-10-26 2001-04-03 Novartis Ag Apparatus, method and composition for cleaning and disinfecting
JP2002534370A (ja) 1998-12-30 2002-10-15 デクセル リミテッド サイクロスポリンを送達するための分散可能な濃縮物
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
WO2000045734A1 (en) 1999-02-02 2000-08-10 Wright Medical Technology, Inc. Controlled release composite
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CA2383572C (en) 1999-10-21 2007-12-11 Alcon Universal Ltd. Sub-tenon drug delivery
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ATE283013T1 (de) * 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
EP1255640B1 (de) 1999-12-28 2008-05-21 Kimberly-Clark Worldwide, Inc. Antimikrobielles wischtuch mit kontrollierter abgabe für harte oberflächen
AU774993B2 (en) 1999-12-28 2004-07-15 Kimberly-Clark Worldwide, Inc. Use-dependent indicator system for absorbent articles
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
US9925087B2 (en) * 2000-09-15 2018-03-27 Bruder Healthcare Company, Llc Wound and therapy compress and dressing
CA2424029C (en) * 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
WO2002056863A2 (en) * 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
EP1847255A3 (de) * 2001-01-03 2009-03-04 Bausch & Lomb Incorporated Vorrichtung zur verzögerten Freigabe von Arzneimitteln mit beschichteten Kernen
US6756058B2 (en) 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
WO2002053129A1 (en) * 2001-01-03 2002-07-11 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
DE60130928T2 (de) * 2001-01-03 2008-07-17 Bausch & Lomb Inc. Vorrichtung zur verzögerten wirkstofffreisetzung mit beschichteten medikamentenkernen
JP2004520900A (ja) * 2001-01-26 2004-07-15 ボシュ・アンド・ロム・インコーポレイテッド 徐放薬剤送達装置の改良製造方法
US7181287B2 (en) * 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP2004536631A (ja) 2001-05-03 2004-12-09 マサチューセッツ・アイ・アンド・イア・インファーマリー 移植可能な薬物送達デバイスおよびその使用
EP1404297B1 (de) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoirvorrichtung für die intraokulare arzneimittelabgabe
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
EP1409065B1 (de) 2001-07-23 2007-01-17 Alcon, Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
AU2002319606B2 (en) * 2001-07-23 2006-09-14 Alcon, Inc. Ophthalmic drug delivery device
US20030158598A1 (en) * 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7217381B2 (en) 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
MXPA04002980A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20060034929A1 (en) * 2001-12-27 2006-02-16 Brubaker Michael J Sustained release drug delivery devices with prefabricated permeable plugs
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
MXPA04008903A (es) * 2002-03-11 2004-11-26 Alcon Inc Sistema de suministro de farmaco implantable.
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
CA2484632C (en) * 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PT1509256E (pt) * 2002-05-24 2009-10-15 Angiotech Int Ag Composições e métodos de revestimento de implantes médicos
US8313760B2 (en) * 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US6976584B2 (en) * 2002-06-26 2005-12-20 Bausch & Lomb Incorporated Package for surgical implant
CN100435880C (zh) * 2003-02-28 2008-11-26 微创医疗器械(上海)有限公司 一种药物洗脱介入医疗器械及其制备方法
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
CN100355455C (zh) * 2002-07-15 2007-12-19 爱尔康公司 用于眼内使用的非聚合亲脂性药物植入组合物
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
EP1539157B1 (de) 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin zur Verwendung in der Hemmung oder Vorbeugung der choroidalen Neovaskularisation
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
AU2003272575B2 (en) * 2002-09-18 2007-11-08 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US20050143363A1 (en) * 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
AU2003301347A1 (en) * 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
WO2004043435A2 (en) * 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CA2510320C (en) 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
AU2004207523A1 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
SI1592408T1 (sl) * 2003-01-24 2010-01-29 Psivida Inc Naprava s podaljšanim sproščanjem in postopek za okularno dajanje adrenergičnih sredstev
ES2338420T3 (es) * 2003-01-24 2010-05-07 Psivida Us Inc. Dispositivo y procedimiento de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica.
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
PL378210A1 (pl) * 2003-02-20 2006-03-20 Alcon, Inc. Zastosowanie steroidów do leczenia osób cierpiących z powodu zaburzeń gałki ocznej
JP2006518383A (ja) * 2003-02-20 2006-08-10 アルコン，インコーポレイテッド 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
US7483750B2 (en) * 2003-03-21 2009-01-27 Second Sight Medical Products, Inc. Transretinal implant and method of implantation
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
US20050261668A1 (en) * 2003-03-28 2005-11-24 Bausch & Lomb Incorporated Drug delivery device
CA2524271C (en) * 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7589107B2 (en) * 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
JP2007500250A (ja) * 2003-06-13 2007-01-11 アルコン，インコーポレイテッド 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
ATE496056T1 (de) 2003-06-16 2011-02-15 Acad Of Science Czech Republic Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
SI1635787T1 (sl) * 2003-06-26 2012-04-30 Psivida Inc Bioeredibilni sistemi za oddajanje zdravil z zadrževanim sproščanjem
ATE536861T1 (de) * 2003-06-26 2011-12-15 Control Delivery Sys Inc Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
ES2315680T3 (es) 2003-06-26 2009-04-01 Psivida Inc. Sistema de distribucion de farmacos de gelificacion in situ.
US20040265356A1 (en) * 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
US20050054586A1 (en) * 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
ZA200508654B (en) * 2003-07-10 2007-01-31 Alcon Inc Ophthalmic drug delivery device
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
ATE460901T1 (de) * 2003-11-13 2010-04-15 Psivida Inc Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut
WO2005051432A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
US20050130906A1 (en) * 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
BRPI0405798B8 (pt) * 2003-11-28 2021-05-25 Halex Istar Ind Farmaceutica L processo de eliminação de resíduos alcalinos presentes no 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amino-1h-purin-6(9h)-ona e apresentação farmacêutica
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
US20050158365A1 (en) 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050137538A1 (en) 2003-12-22 2005-06-23 Bausch & Lomb Incorporated Drug delivery device
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
JP2007519724A (ja) * 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド 核酸を基剤とする治療剤の制御送達および持続的送達
US20060018949A1 (en) * 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
CN1972958B (zh) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
CN101027045A (zh) * 2004-04-13 2007-08-29 阿尔扎公司 基于芬太尼药物的透皮释放装置和方法
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
AU2005269988B2 (en) * 2004-07-02 2012-02-02 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
ATE439123T1 (de) * 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
CA2573702C (en) 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
US20060020253A1 (en) * 2004-07-26 2006-01-26 Prescott Anthony D Implantable device having reservoir with controlled release of medication and method of manufacturing the same
CA2573892A1 (en) * 2004-07-26 2006-02-09 Clarity Corporation Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
WO2006023130A2 (en) * 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
CA2581126A1 (en) 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20060068012A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
WO2006039459A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
WO2006039333A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
US20060078592A1 (en) * 2004-10-12 2006-04-13 Bausch & Lomb Incorporated Drug delivery systems
US20070276481A1 (en) * 2004-12-08 2007-11-29 Renner Steven B Drug delivery device
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
WO2006068898A1 (en) * 2004-12-22 2006-06-29 Bausch & Lomb Incorporated Reusable drug delivery device
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
KR20070101865A (ko) * 2004-12-22 2007-10-17 알콘, 인코퍼레이티드 안과용 약물 전달 장치
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
KR101387456B1 (ko) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 질환 또는 상태의 치료를 위한 액체 제제
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
WO2006110487A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants for subretinal delivery
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
US20060292222A1 (en) * 2005-06-21 2006-12-28 Matthew Jonasse Drug delivery device having zero or near zero-order release kinetics
US20060292202A1 (en) * 2005-06-27 2006-12-28 Bausch & Lomb Incorporated Drug delivery device
CN101600475A (zh) 2005-07-27 2009-12-09 佛罗里达大学研究基金会有限公司 修正蛋白质错误折叠的小型化合物及其使用
EP1929021A2 (de) * 2005-08-31 2008-06-11 Genvec, Inc. Malariaimpfstoffe auf adenovirusvektorbasis
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals Inc métodos de tratamento de cáncer
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
US20070122449A1 (en) * 2005-11-28 2007-05-31 Choonara Yahya E Biodegradable implantable drug delivery device
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7981096B2 (en) * 2006-05-12 2011-07-19 David Castillejos Optic nerve head implant and medication delivery system
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
MX2009001334A (es) 2006-08-07 2009-02-13 Bausch & Lomb Tratamiento de infecciones y secuelas de las mismas con agonistas de receptor de glucocorticoide disociado y agentes anti-infecciosos, combinados.
US20100105707A1 (en) * 2006-08-23 2010-04-29 The United States Of America Method of treating or preventing oxidative stress-related disease
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008027796A2 (en) * 2006-08-31 2008-03-06 Bausch & Lomb Incorporated Compositions and methods for treating or preventing glaucoma or progression thereof
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
ES2361585T3 (es) * 2006-09-11 2011-06-20 BAUSCH & LOMB INCORPORATED Composiciones y métodos para tratar, controlar, reducir, mejorar o prevenir la alergia.
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100278870A1 (en) * 2007-01-09 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Adenoviral vector-based malaria vaccines
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2136863A2 (de) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Vorrichtung zur abgabe von arzneimitteln und relevante verbindungen
MX2009010000A (es) * 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) * 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
US7910123B2 (en) * 2007-09-05 2011-03-22 Warsaw Orthopedic Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent
US20090062922A1 (en) * 2007-09-05 2009-03-05 Mckay William F Method and apparatus for delivering treatment to a joint
KR101996336B1 (ko) * 2007-09-07 2019-07-04 마티 테라퓨틱스 인코포레이티드 치료 약제의 서방성 약물 코어
US20090087443A1 (en) 2007-09-27 2009-04-02 Bartels Stephen P Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
TWI498136B (zh) * 2007-10-09 2015-09-01 Alcon Res Ltd 用於遞送速率及溫度相依性物質至眼睛的注射器及其製備方法
TWI451862B (zh) * 2007-10-09 2014-09-11 Alcon Res Ltd 用於眼睛注射的熱係數驅動藥丸尺寸
JP5330401B2 (ja) * 2007-11-08 2013-10-30 アリメラ・サイエンシーズ，インコーポレーテッド 眼のための埋め込み装置、及びその装置を備えるキット
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
JP5639895B2 (ja) 2007-12-27 2014-12-10 インフィニティ ファーマスーティカルズ、インク． 立体選択的還元方法
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009105692A1 (en) 2008-02-21 2009-08-27 Rutgers, The State University Of New Jersey Compositions and methods for treating ophthalmic diseases
US20100152646A1 (en) * 2008-02-29 2010-06-17 Reshma Girijavallabhan Intravitreal injection device and method
EP2276439A4 (de) 2008-05-12 2013-11-27 Univ Utah Res Found Vorrichtung und entsprechende verfahren zur intraokularen medikamentenverabreichung
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
WO2010024930A2 (en) * 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US7985208B2 (en) * 2008-09-18 2011-07-26 Oasis Research LLC Ring shaped contoured collagen shield for ophthalmic drug delivery
BRPI0916125A2 (pt) 2008-11-07 2015-11-03 Insuline Medical Ltd "dispositivo de tratamento"
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US8372036B2 (en) * 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2010135369A1 (en) * 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
ES2921527T3 (es) 2009-06-03 2022-08-29 Forsight Vision5 Inc Administración de fármaco en segmento anterior
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
BR122017013201B1 (pt) 2009-11-09 2018-05-15 Allergan, Inc. Composição para a estimulação de crescimento capilar
US9205091B2 (en) 2009-11-13 2015-12-08 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
US8177747B2 (en) * 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
EP2533737B1 (de) 2010-02-08 2014-01-08 On Demand Therapeutics, Inc. Laseraktivierte wirkstofffreisetzungsvorrichtung mit geringer permeabilität
US8524762B2 (en) 2010-03-08 2013-09-03 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
US9682133B2 (en) 2010-03-17 2017-06-20 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011116336A1 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxyl (hno) releasing compounds and uses thereof in treating diseases
EP2383286A1 (de) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und Zusammensetzungen zur Behandlung von degenerativen Netzhauterkrankungen
WO2011146483A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
WO2011159824A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
EP3861969A1 (de) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injektorvorrichtung zur arzneimittelabgabe
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
US8697056B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8821457B2 (en) * 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (de) 2010-12-20 2019-02-20 GenVec, Inc. Auf adenovirusvektor basierender impfstoff gegen denguefieber
WO2012088306A2 (en) * 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
EP2675491A2 (de) 2011-02-17 2013-12-25 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2678022A2 (de) 2011-02-23 2014-01-01 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
US9012647B2 (en) 2011-04-07 2015-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
WO2012149452A1 (en) 2011-04-29 2012-11-01 Regents Of The University Of Michigan Compounds, formulations, and methods of protein kinase c inhibition
CN105349492B (zh) 2011-05-18 2019-04-16 加利福尼亚大学董事会 用于治疗视网膜疾病的组合物及方法
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6068454B2 (ja) 2011-06-06 2017-01-25 オーク・クレスト・インスティテュート・オブ・サイエンスＯａｋ Ｃｒｅｓｔ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｓｃｉｅｎｃｅ ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス
US20120316199A1 (en) 2011-06-07 2012-12-13 Ward Keith W Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EA032666B1 (ru) 2011-06-14 2019-06-28 Бикам Фармасьютикалз, Инк. Опсинсвязывающие лиганды и способы их применения
EP4249059A3 (de) 2011-06-28 2023-11-29 ForSight Vision4, Inc. Vorrichtung zum sammeln einer flüssigkeitsprobe aus einer reservoirkammer einer therapeutischen vorrichtung für das auge
WO2013023115A1 (en) 2011-08-10 2013-02-14 On Demand Therapeutics, Inc. Laser-activated drug delivery device
WO2013040238A2 (en) 2011-09-13 2013-03-21 Vista Scientific Llc Sustained release ocular drug delivery devices and methods of manufacture
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US8685106B2 (en) 2011-11-15 2014-04-01 Abraham Lin Method of a pharmaceutical delivery system for use within a joint replacement
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862746A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
EP2806828B1 (de) 2012-01-24 2021-07-21 The Regents of The University of Colorado, A Body Corporate Entwürfe und verfahren für modulare intraokularlinsen
US9364316B1 (en) * 2012-01-24 2016-06-14 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US10028824B2 (en) 2012-01-24 2018-07-24 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US10080648B2 (en) 2012-01-24 2018-09-25 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP2811952A1 (de) 2012-02-07 2014-12-17 On Demand Therapeutics, Inc. Wirkstofffreisetzungsvorrichtungen und verwendungsverfahren dafür
EP2814482A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2814510A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013124477A1 (en) 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
WO2013154744A1 (en) 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (es) 2012-06-01 2017-10-06 Surmodics Inc Aparato y método para recubrir catéteres con globo.
WO2014049071A1 (en) 2012-09-26 2014-04-03 Tangent Reprofiling Limited Modulators of androgen synthesis
US20140100249A1 (en) 2012-10-09 2014-04-10 Douglas Sears Therapeutic Treatment
US9539240B2 (en) 2012-10-24 2017-01-10 Biocopea Limited Drug combinations and methods for reducing or maintaining cholesterol or HDL/LDL levels
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
PT2911623T (pt) 2012-10-26 2019-11-21 Forsight Vision5 Inc Sistema oftálmico para libertação prolongada de fármaco no olho
WO2014093270A1 (en) 2012-12-10 2014-06-19 Virginia Commonwealth University Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
AU2014204733B2 (en) 2013-01-14 2016-09-08 Clinics Operations Limited Cancer drug and uses
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
EP2968613B1 (de) 2013-03-11 2019-09-11 University of Florida Research Foundation, Inc. Freisetzung von card-protein zur behandlung von augenentzündungen
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9987233B2 (en) 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
EP4302736A3 (de) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmisches implantat zur abgabe von therapeutischen substanzen
US10098836B2 (en) 2013-05-02 2018-10-16 Retina Foundation Of The Southwest Method for forming a molded two-layer ocular implant
WO2015035190A1 (en) 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
EA201891279A1 (ru) 2013-12-24 2019-01-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
WO2015112739A1 (en) 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
JP2017505702A (ja) 2014-02-18 2017-02-23 クラービスタ メディカル, インコーポレイテッドClarvista Medical, Inc. モジュール式眼内レンズの設計、器具および方法
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2016005599A1 (en) 2014-07-10 2016-01-14 Biocopea Limited Compositions, methods and uses for treating gender-biased immune disorders
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
EP3250152A1 (de) 2015-01-30 2017-12-06 Clarvista Medical, Inc. Entwürfe für modulare intraokularlinse
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
EP3283004A4 (de) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Augeneinsatzzusammensetzung aus einem semikristallinen oder kristallinen pharmazeutischen wirkstoff
EP3294298A4 (de) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin-analoga, synthese und verwendungen
US11447797B2 (en) 2015-05-12 2022-09-20 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service AAV with unique capsid protein VP1 and methods of using for treatment
KR20180014051A (ko) 2015-05-28 2018-02-07 코넬 유니버시티 혈관 부종 치료제로서의 아데노-관련 바이러스 매개 c1e1의 전달
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
US10202429B2 (en) 2015-06-08 2019-02-12 Retinal Solutions Llc Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
US10669321B2 (en) 2015-06-08 2020-06-02 Retinal Solutions Llc Retinal capillary regeneration with synthetic norrin protein
US10206978B2 (en) 2015-06-08 2019-02-19 Retinal Solutions Llc Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
EP3316889A4 (de) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin-analoga sowie synthese und verwendungen davon
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3206672B1 (de) 2015-10-27 2018-03-14 Eupraxia Pharmaceuticals Inc. Retard-formulierungen von lokalanästhetika
KR102489706B1 (ko) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
WO2017079449A1 (en) 2015-11-04 2017-05-11 Clarvista Medical, Inc. Modular intraocular lens designs, tools and methods
WO2017082946A1 (en) 2015-11-13 2017-05-18 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
CN108430405B (zh) 2015-11-20 2021-04-13 弗赛特影像4股份有限公司 用于缓释药物递送装置的多孔结构
CA3014774A1 (en) 2016-02-17 2017-08-24 Children's Medical Center Corporation Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
JP7169647B2 (ja) 2016-03-10 2022-11-11 アイオー セラピューティクス インコーポレイテッド Ｒｘｒアゴニストおよび甲状腺ホルモンの組み合わせでの筋肉障害の治療
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
AU2017252294B2 (en) 2016-04-20 2021-12-02 Dose Medical Corporation Bioresorbable ocular drug delivery device
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
US11045309B2 (en) 2016-05-05 2021-06-29 The Regents Of The University Of Colorado Intraocular lens designs for improved stability
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
US11523940B2 (en) 2017-03-17 2022-12-13 W. L. Gore & Associates, Inc. Delivery aids for glaucoma shunts
WO2018226640A1 (en) 2017-06-05 2018-12-13 The Regents Of The University Of The University Of California Compositions for treating retinal diseases and methods for making and using them
US11382736B2 (en) 2017-06-27 2022-07-12 Alcon Inc. Injector, intraocular lens system, and related methods
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
EP3692154A1 (de) 2017-10-02 2020-08-12 Genedit Inc. Modifizierte cpf1-guide-rnas
CA3079409A1 (en) 2017-10-18 2019-04-25 Washington University Dominant negative sarm1 molecules as a therapeutic strategy for neurodegenerative diseases or disorders
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
KR20200105494A (ko) 2017-12-29 2020-09-07 코넬 유니버시티 호산구성 장애에 대한 유전자 요법
CN112236516A (zh) 2018-04-03 2021-01-15 康奈尔大学 针对氧化应激的基因疗法
US20200268554A1 (en) * 2018-05-12 2020-08-27 Goldenbiotech, Llc Self-Retaining Implantable Drug Delivery Device
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CA3108324A1 (en) 2018-07-31 2020-02-06 Cornell University Gene therapy methods to control organ function
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
US11039954B2 (en) 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
WO2021022208A1 (en) 2019-08-01 2021-02-04 Kaplitt Michael G Targeted gene therapy to treat neurological diseases
WO2021076794A1 (en) 2019-10-15 2021-04-22 Cornell University Methods for modulating level of expression from gene therapy expression cassette
EP4045653A1 (de) 2019-10-16 2022-08-24 Cornell University Gentherapie für morbus alzheimer
WO2021086973A2 (en) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
WO2021108809A1 (en) 2019-11-25 2021-06-03 Cornell University Apoe gene therapy
EP4118202A1 (de) 2020-03-20 2023-01-18 Athanor Biosciences, Inc. Impfstoffe auf bakteriophagenbasis und manipulierter bakteriophagen
EP4127165A1 (de) 2020-04-05 2023-02-08 Athanor Biosciences, Inc. Antikörper auf bakteriophagenbasis und proteinbasierte bindemittel
CA3176547A1 (en) 2020-04-23 2021-10-28 Milad ROUHIMOGHADAM Gper proteolytic targeting chimeras
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
US20230374483A1 (en) 2020-07-08 2023-11-23 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
WO2022036104A1 (en) 2020-08-12 2022-02-17 University Of Iowa Research Foundation Insulin sensitizers for the treatment of diabetes mellitus
US20230293678A1 (en) 2020-08-21 2023-09-21 Aliasger K. Salem Cationic nanoparticle adjuvants
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
EP4340894A1 (de) 2021-05-21 2024-03-27 University Of Iowa Research Foundation Antioxidationsmittelhaltige partikel und verfahren zur verwendung
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
US11357620B1 (en) 2021-09-10 2022-06-14 California LASIK & Eye, Inc. Exchangeable optics and therapeutics
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers
WO2023130022A2 (en) 2021-12-29 2023-07-06 University Of Iowa Research Foundation Cystatin rna compositions for tissue engineering
WO2023164727A1 (en) 2022-02-28 2023-08-31 University Of Iowa Research Foundation A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3896819A (en) * 1969-04-01 1975-07-29 Alejandro Zaffaroni IUD having a replenishing drug reservoir
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3632739A (en) * 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
US3980463A (en) * 1970-11-16 1976-09-14 Sumitomo Chemical Company, Limited Process for producing granular composition for use in agriculture and horticulture
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4036227A (en) * 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US4096238A (en) * 1974-12-23 1978-06-20 Alza Corporation Method for administering drug to the gastrointestinal tract
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4247498A (en) * 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4519909A (en) * 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
US4290426A (en) * 1978-05-04 1981-09-22 Alza Corporation Dispenser for dispensing beneficial agent
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4730013A (en) * 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DK90883A (da) * 1982-03-18 1983-09-19 Merck & Co Inc Beholder til osmotisk afgivelse af et stof eller en stofblanding
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
EP0147780A3 (de) * 1984-01-03 1987-03-11 Merck & Co. Inc. Vorrichtung zur Freisetzung von Arzneistoffen
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4927687A (en) * 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4717567A (en) * 1985-11-25 1988-01-05 Eastman Kodak Company Rumen-stable pellets
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4786500A (en) * 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
JPH0794384B2 (ja) * 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
IT1223150B (it) * 1987-11-18 1990-09-12 Ubaldo Conte Compressa per uso oftalmico e rilascio controllato della sostanza attiva
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
EP0514406B1 (de) * 1990-01-30 1994-03-02 Akzo Nobel N.V. Gegenstand zur gesteuerten wirkstoffabgabe mit einem von einer wand völlig umschlossenen hohlraum und völlig oder teilweise mit einem oder mehreren wirkstoffen gefüllt
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IS3778A7 (is) * 1990-10-31 1992-05-02 Amgen Inc. Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt

Also Published As

Publication number Publication date
DE69227187D1 (de) 1998-11-05
ATE171617T1 (de) 1998-10-15
EP0577646A4 (en) 1994-06-01
WO1992014450A1 (en) 1992-09-03
DK0861659T3 (da) 2011-08-29
EP0577646A1 (de) 1994-01-12
AU1419792A (en) 1992-09-15
ATE511832T1 (de) 2011-06-15
ES2366573T3 (es) 2011-10-21
EP0861659A1 (de) 1998-09-02
EP0577646B1 (de) 1998-09-30
AU660012B2 (en) 1995-06-08
JP2003002825A (ja) 2003-01-08
ES2125259T3 (es) 1999-03-01
JP3908592B2 (ja) 2007-04-25
JPH06505274A (ja) 1994-06-16
EP0861659B1 (de) 2011-06-08
CA2104699C (en) 2008-02-12
DK0577646T3 (da) 1999-06-21
US5378475A (en) 1995-01-03
CA2104699A1 (en) 1992-08-22

Similar Documents

Publication Publication Date Title
DE69227187D1 (de) Arzneistoffabgabesysteme mit verzögerter freisetzung
YU11100A (sh) Sistemi koji obezbeđuju podržano oslobađanje leka
DE60135907D1 (de) Wirkstoffverabreichungssysteme mit verzögerter freisetzung, verwendung und verfahren zur herstellung derselben
CA2230947A1 (en) Implantable controlled release device to deliver drugs directly to an internal portion of the body
DK156289A (da) Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel
ATE409024T1 (de) Formulierungen mit kontrollierter abgabe überzogen mit wässrigen dispersionen von ethylcellulose
DE60042352D1 (de) Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
NZ313984A (en) Transcorneal drug-release system with multiple microblades and pump
GB8919448D0 (en) Controlled release device with an impermeable coating having an orifice for release of drug
YU48229B (sh) Postupak za izradu flastera kao transdermalnog terapijskog sistema za dirigovano, stupnjevito davanje aktivnih materija preko kože
GEP19991819B (en) Method for Production of Therapeutic Form of Carbamazepin with Retarded Active Substance Release
ATE64539T1 (de) Dermale und transdermale therapeutische systeme mit musterfoermig aufgetragener klebschicht, sowie verfahren zur dessen herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition